Tagged with Biopole

France European biotech’s recent struggles are well documented. Deep-pocketed investors with sufficient risk tolerance to fund potentially breakout companies are thin on the ground, and Europe is losing touch with both the US and China every year; recent data from ING shows that the percentage of global new drug approvals originating…

France France’s historical contribution to medical research is almost unparalleled globally, with 13 winners of the annual Nobel Prize for Physiology or Medicine, and even more for Chemistry. Most famously, Louis Pasteur’s work on germ theory and pasteurisation in the 19th century laid the groundwork for much of what we know…

France Erick Lelouche has served as President of Lyonbiopôle since February 2025, bringing more than 35  years of experience in the pharmaceutical industry across Pfizer and Boehringer Ingelheim, spanning human and animal health in France, Germany, and the US. Together with General Manager Teddy Breyton, whose background lies in regional economic…

Switzerland With the Trump administration imposing tariffs of up to 39 percent on Swiss goods (recently reduced to 15 percent), the pressure on Switzerland’s most influential industrial sector – pharmaceuticals – has undoubtedly intensified. Yet the industry continues to wield a super-size effect on the local economy, contributing up to a…

Switzerland For a tiny Alpine nation nestled deep in the interior of continental Europe, Switzerland boasts a spectacularly vibrant biotech scene. This is because “the country manages to leverage its compact geography to achieve unprecedented levels of collaboration across key innovation hubs, rendering it possible to forge strong networks and partnerships…

Switzerland Nasri Nahas, CEO of Biopôle, shares his vision for one of Europe’s leading life sciences innovation parks and its evolving role within the national and international healthcare ecosystem. In this interview, Nasri discusses Biopôle’s key priorities, including the integration of AI and data, sustainability in life sciences, and the importance…

France Christophe Cizeron, president of Lyonbiopole, discusses the important economic and industrial position of the research cluster in the Rhone-Alps Region as well as the challenges posed by domestic and international competition.   Between 2007-2016, the number of biotech companies doubled in the Lyon region and there was a sharp increase…

Switzerland Nasri Nahas, CEO of Biopôle in Switzerland, discusses his motivations for joining the biotech, and his mission to re-position the organization as a life sciences ecosystem bringing together academia, business, and research. What motivated you to join Biopôle in October 2015? I began my career as a molecular biologist in France…

Pharma Lyonbiopole was established in 2005 as a cluster designed to support the local business community focused on infectious diseases and microbiology. Philippe Archinard, the Biopole’s president, traces the evolution of the cluster over the last decade while underscoring the critical importance of transparency and collaboration between government, industry and academia.…

Lyonbiopôle As a majority of our readers are American that may be used to a different model of clusters can you explain the unique characteristics of the pôles de compétitivité?  The biggest differentiating point is that the clusters have been founded on government initiative to create competitive zones across multiple industries.…